Financiële Diensten Amsterdam (FDA)

What Financiële Diensten Amsterdam (FDA) does

Financiële Diensten Amsterdam (FDA) is an independent Dutch investment research firm founded in 1986 and headquartered in Amsterdam, providing research and advisory services exclusively to professional investors such as pension funds, asset managers, family offices, charitable foundations, and regulatory/government entities. Retail investors are explicitly excluded. The company operates with a flat organization of approximately 22 staff, including a team of about 20 financial analysts and portfolio managers.

FDA's core product is FDA Consultancy, an online research portal that delivers daily analyses of more than 100 internationally operating companies, asset allocation views, risk-return profiles, and a macroeconomic module grounded in a proprietary flow-of-funds methodology that tracks money, liquidity, and capital flows to assess shifts in relative power across equities, bonds, and currencies. The firm also maintains a proprietary Corporate Sustainability Assessment applied to all covered companies (with governance, social, and environmental sub-scores and CO2 tracking) and an in-house risk concept that diverges from standard statistical price-history-based risk models. These research outputs feed six model portfolios: FDA Blue Chips Equity (since June 2003), FDA Credit (since August 2003), FDA Sustainability (since December 2004), FDA Total Return (since September 2005), FDA Sovereign Plus Bond (since December 2011), and FDA Essential Selection (since February 2014). FDA also publishes the FDA Blue Chips Index covering 350 stocks with 11 sector sub-indices, under license from FTSE International.

FDA's business model is fee-for-service with no transactional compensation: clients pay directly on contract basis for FDA Consultancy access, full portfolio advisory services including personal consulting and periodic reporting for equity and bond portfolios, and bespoke custom research engagements. Pricing is not publicly disclosed and is tailored to client scope. The firm has no external funding, no parent company, and no disclosed revenue. FDA has announced it will cease operations by the end of June 2026, citing consolidation in the Dutch asset management industry and the increasing role of foreign parties as the rationale for the wind-down.

Name

Financiële Diensten Amsterdam (FDA)

Legal name

Financiële Diensten Amsterdam B.V.

Website

https://fda.nl

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

11–50 employees

Short description

FDA is a Dutch independent investment research firm founded in 1986, serving institutional investors (pension funds, asset managers, family offices, foundations, regulators) with proprietary flow-of-funds research, sustainability analysis, and model portfolios. Operations are ceasing by end of June 2026.

Ownership category

akta.pro rank

Product category

Investment Research & Advisory

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Strategy & Thematic Research (FSACAGAG)

akta.pro secondary industry

Industry & Sector Research (Syndicated/Custom) (BPAHALAE)

Keywords

• Independent investment research
• Portfolio advisory services
• Sustainability assessment framework
• Model portfolio construction
• Equity research analysis

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Investment Research & Advisory Services: FDA generates revenue through direct client payments for research and advisory services. FDA is not a securities broker and does not receive income from client transactions. Services include contract-based access to FDA Consultancy, full portfolio advisory, and custom research work. Clients pay directly for advice and research on a contractual basis.
2. FDA Consultancy Portal Subscription: Contract-based access to FDA Consultancy, an online research portal for institutional investors providing daily analyses of over 100 internationally operating companies, risk-return profiles, sustainability analysis, and macroeconomic module with flow-of-funds analysis.
3. Portfolio Advisory Services: Full portfolio advisory service including access to FDA Consultancy, personal advisory, and periodic reporting for both equity and bond portfolios. Targets pension funds, asset managers, family offices, and charitable foundations.
4. Custom Research & Reporting: Custom work on request including periodic company reports, FDA sustainability reporting, various information modules based on client-specific criteria, and advisory work for regulatory and government entities.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

FDA provides independent investment research and portfolio advisory services to professional investors. Its core offering is the FDA Consultancy online research portal, which delivers daily analyses of more than 100 internationally operating companies, asset-allocation views on equities, bonds and currencies, and macroeconomic insights derived from a proprietary flow-of-funds methodology. This research underpins a suite of equity and bond model portfolios, the proprietary FDA Blue Chips Index, and full portfolio advisory mandates including personalized advice and periodic reporting.

Product overview

FDA (Financiële Diensten Amsterdam) is an independent investment research company that offers a platform of research and advisory services for professional investors. The core offering is FDA Consultancy, an online research portal providing daily analyses of over 100 internationally operating companies and macroeconomic insights based on a flow-of-funds methodology. This research feeds into a suite of six model portfolios: FDA Blue Chips Equity Portfolio (launched 2003), FDA Sustainability Portfolio (launched 2004), FDA Essential Selection Portfolio (launched 2014), FDA Credit Portfolio (launched 2003), FDA Sovereign Plus Bond Portfolio (launched 2011), and FDA Total Return Portfolio (launched 2005). FDA also maintains the FDA Blue Chips Index (covering 350 stocks) plus 11 sector indices, and provides full portfolio advisory services with personalized advice and periodic reporting. All research incorporates the proprietary FDA Corporate Sustainability Assessment framework. FDA is ceasing operations at the end of June 2026 after 40 years of independent Dutch investment research.

Differentiator

Problem solved

Functional benefit

Products and services

• FDA Consultancy

Quantifiable outcome

• FDA Blue Chip Equity Portfolio: 1,187.5% cumulative return (annualized 11.8%) vs 671.8% benchmark (annualized 9.3%) over average period 1, demonstrating long-term outperformance
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• European Association of Independent Research Providers (EuroIRP)minorOthers · 1 January 1986FDA is a member of the European Association of Independent Research Providers (EuroIRP), an industry association for independent investment research providers in Europe. This membership provides industry networking and recognition.

Scale indicators6 records

Recent moves6 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/financi-le-diensten-amsterdam

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Financiële Diensten Amsterdam (FDA)